EUVIMEDEUVIMED entdecken
Open Access

Mineralocorticoid receptor antagonism prevents coronary microvascular dysfunction in intermittent hypoxia independent of blood pressure

Mohammad Badran iD, Abdelnaby Khalyfa iD, Chastidy A Bailey, David Gozal iD, Shawn B Bender iD

SLEEP · 2025

DOI: 10.1093/sleep/zsae296 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLEEP, 2025. Verfasst von Mohammad Badran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Missouri; Columbia, MO, USA. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Hypoxia, Spironolactone, Coronary Vessels. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH, Harry S Truman Memorial Veterans Hospital in Columbia, MO.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives Obstructive sleep apnea (OSA), is characterized by intermittent hypoxia (IH), and is associated with increased cardiovascular mortality that may not be reduced by standard therapies. Inappropriate activation of the renin-angiotensin-aldosterone system occurs in IH, and mineralocorticoid receptor (MR) blockade has been shown to improve vascular outcomes in cardiovascular disease. Thus, we hypothesized that MR inhibition prevents coronary and renal vascular dysfunction in mice exposed to chronic IH.

Methods

Human and mouse coronary vascular cells and male C57BL/6J mice were exposed to IH or room air (RA) for 12 hours/day for 3 days (in vitro) and 6 weeks with or without treatments with spironolactone (SPL) or hydrochlorothiazide (HTZ).

Results

In vitro studies demonstrated that IH increased MR gene expression in human and mouse coronary artery endothelial and smooth muscle cells. Exposure to IH in mice increased blood pressure, reduced coronary flow velocity reserve (CFVR), attenuated endothelium-dependent dilation, and enhanced vasoconstrictor responsiveness in coronary, but not renal arteries. Importantly, SPL treatment prevented altered coronary vascular function independent of blood pressure as normalization of BP with HTZ did not improve CFVR or coronary vasomotor function.

Conclusions

These data demonstrate that chronic IH, which mimics the hypoxia-reoxygenation cycles of moderate-to-severe OSA, increases coronary vascular MR expression in vitro. It also selectively promotes coronary vascular dysfunction in mice. Importantly, this dysfunction is sensitive to MR antagonism by SPL, independent of blood pressure. These findings suggest that MR blockade could serve as an adjuvant therapy to improve long-term cardiovascular outcomes in patients with OSA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mineralocorticoid Receptor AntagonistsHypoxiaSpironolactoneCoronary VesselsBlood PressureAnimalsMaleMiceMice, Inbred C57BLHumansSleep Apnea, ObstructiveHydrochlorothiazideReceptors, Mineralocorticoid

Stichwörter der Autor:innen

blood pressurecoronary microvascular diseaseintermittent hypoxiamineralocorticoid receptorobstructive sleep apneaspironolactone

Substanzen

Mineralocorticoid Receptor AntagonistsSpironolactoneHydrochlorothiazideReceptors, Mineralocorticoid

Autor:innen und Institutionen

  • Department of Pediatrics, University of Missouri; Columbia, MO, USA.
  • Department of Medical Physiology and Pharmacology, University of Missouri; Columbia, MO, USA.
  • Department of Biomedical Sciences, Marshall University; Huntington, WV, USA.
  • Department of Biomedical Sciences, University of Missouri; Columbia, MO, USA.
  • Research Service, Harry S. Truman Memorial Veterans Hospital; Columbia, MO, USA.
  • Office of the Dean, Joan C. Edwards School of Medicine, Marshall University; Huntington, WV, USA.

ORCID-Profile: Mohammad Badran, Abdelnaby Khalyfa, David Gozal, Shawn B Bender

Förderung

  • NHLBI NIH HHS
  • NIH
  • Harry S Truman Memorial Veterans Hospital in Columbia, MO

Zitieren

APA

Badran, M., Khalyfa, A., Bailey, C. A., Gozal, D., & Bender, S. B. (2025). Mineralocorticoid receptor antagonism prevents coronary microvascular dysfunction in intermittent hypoxia independent of blood pressure. SLEEP. https://doi.org/10.1093/sleep/zsae296

Vancouver

Badran M, Khalyfa A, Bailey CA, Gozal D, Bender SB. Mineralocorticoid receptor antagonism prevents coronary microvascular dysfunction in intermittent hypoxia independent of blood pressure. SLEEP. 2025. doi:10.1093/sleep/zsae296

BibTeX
@article{Badran2025,
  author = {Badran, Mohammad and Khalyfa, Abdelnaby and Bailey, Chastidy A and Gozal, David and Bender, Shawn B},
  title = {Mineralocorticoid receptor antagonism prevents coronary microvascular dysfunction in intermittent hypoxia independent of blood pressure},
  journal = {SLEEP},
  year = {2025},
  doi = {10.1093/sleep/zsae296}
}
Kostenlos starten →